Skip to navigation Skip to content

Zinbryta - WITHDRAWN FROM MARKET -- MARCH 2, 2018

Share

About this Medication
  • Brand Name: Zinbryta™
  • Chemical Name: daclizumab (dak-li-zoo-mab)
  • Usage in MS: Disease-Modifying Agent
  • Generic Available: No

Zinbryta (daclizumab) was withdrawn from the worldwide market on March 2, 2018. Please see important information about the withdrawal in our Society News.

Description

Zinbryta™ is a laboratory-created monoclonal antibody. It is designed to inhibit certain inflammatory functions of T cells and increase important immune cells that help regulate the immune system.  
Zinbryta is approved by the U.S. Food and Drug Administration (FDA) to treat adult patients with relapsing forms of MS. It should be reserved for people who have had an inadequate response to two or more disease-modifying medications.  
 
Click here to read the Zinbryta Prescribing Information for healthcare professionals.
Click here to read the Zinbryta Medication Guide for patients.

Support

Financial Assistance Program

Zinbryta (daclizumab) was withdrawn from the worldwide market on March 2, 2018. Please see important information about the withdrawal in our Society News.


Share